EQ - NASDAQ

Equillium, Inc.

EQ·NASDAQ

$3.15

-1.6%

HealthcareBiotechnology

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$111.89M

EPS-0.3900

P/E Ratio-8.08

Earnings Date08/12/2026

eq

Depreciation and Amortization

Last Annual Value

116.00K

3-Year CAGR

-1%

5-Year CAGR

21%

10-Year CAGR

99%

Adjust for Inflation

Equillium, Inc. Competitors Analysis of Depreciation and Amortization

EQ · NASDAQ

Company	Depreciation and Amortization	CAGR 3Y	CAGR 5Y	CAGR 10Y
Equillium, Inc. NASDAQ:EQ	116.00K	-2.7%	10.0%	N/A
NRx Pharmaceuticals, Inc. NASDAQ:NRXP	143.00K	205.8%	134.9%	N/A
Outlook Therapeutics, Inc. NASDAQ:OTLK	117.05B	13736.5%	1248.9%	194.4%
CalciMedica, Inc. NASDAQ:CALC	58.00K	0.0%	-35.5%	N/A
PDS Biotechnology Corporation NASDAQ:PDSB	1.55B	4373.3%	1137.4%	162.5%
Q32 Bio Inc. NASDAQ:QTTB	25.00K	-63.1%	-69.5%	-20.2%
Century Therapeutics, Inc. NASDAQ:IPSC	13.10M	0.1%	28.4%	N/A
Telomir Pharmaceuticals, Inc. Common Stock NASDAQ:TELO	0.00	N/A	N/A	N/A
Cue Biopharma, Inc. NASDAQ:CUE	958.00K	-34.7%	N/A	16.8%
OS Therapies Incorporated NYSE:OSTX	2.78K	-13.0%	28.1%	N/A
Coeptis Therapeutics, Inc. NASDAQ:COEP	1.22M	5.7%	22.3%	N/A

Equillium, Inc. Fair Value Envelope

EQ · NASDAQ

Our analysis suggests that EQ has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $3.15, this represents a potential HIDDEN relative to our calculated worth for Equillium, Inc..

HIDDEN

Intrinsic Value

Current Price: $3.15

Related Guides

Blog Categories

Continue your EQ research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.